BNP PARIBAS ASSET MANAGEMENT Holding S.A. Buys Shares of 787,785 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 787,785 shares of the company’s stock, valued at approximately $15,165,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned about 0.92% of Syndax Pharmaceuticals at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. increased its position in Syndax Pharmaceuticals by 13.6% in the 1st quarter. Vanguard Group Inc. now owns 4,926,984 shares of the company’s stock worth $117,262,000 after purchasing an additional 591,631 shares during the last quarter. Sofinnova Investments Inc. lifted its stake in Syndax Pharmaceuticals by 33.9% in the second quarter. Sofinnova Investments Inc. now owns 2,153,669 shares of the company’s stock valued at $44,215,000 after acquiring an additional 545,129 shares during the last quarter. First Turn Management LLC grew its position in Syndax Pharmaceuticals by 85.4% in the third quarter. First Turn Management LLC now owns 1,187,165 shares of the company’s stock worth $22,853,000 after acquiring an additional 546,776 shares in the last quarter. Millennium Management LLC increased its stake in shares of Syndax Pharmaceuticals by 56.3% during the 2nd quarter. Millennium Management LLC now owns 1,065,508 shares of the company’s stock worth $21,875,000 after purchasing an additional 383,634 shares during the last quarter. Finally, Iron Triangle Partners LP bought a new position in shares of Syndax Pharmaceuticals during the 1st quarter valued at $23,159,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on SNDX shares. UBS Group began coverage on shares of Syndax Pharmaceuticals in a research report on Thursday, October 24th. They set a “buy” rating and a $37.00 target price on the stock. HC Wainwright increased their price objective on Syndax Pharmaceuticals from $49.00 to $51.00 and gave the company a “buy” rating in a report on Monday, November 18th. Barclays boosted their target price on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the stock an “overweight” rating in a report on Thursday, August 15th. The Goldman Sachs Group increased their price target on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Finally, StockNews.com cut shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. One analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $37.64.

Syndax Pharmaceuticals Price Performance

NASDAQ SNDX opened at $16.09 on Friday. The company’s fifty day moving average is $18.60 and its two-hundred day moving average is $20.00. The firm has a market capitalization of $1.37 billion, a price-to-earnings ratio of -4.43 and a beta of 0.92. Syndax Pharmaceuticals, Inc. has a 52-week low of $15.00 and a 52-week high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.13) by $0.15. The firm had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.16 million. During the same period last year, the company earned ($0.73) EPS. As a group, sell-side analysts expect that Syndax Pharmaceuticals, Inc. will post -3.69 earnings per share for the current fiscal year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).